Pacific Biosciences Of California (PACB) Cash from Operations (2010 - 2026)

Pacific Biosciences Of California's Cash from Operations history runs 17 years deep, the most recent figure standing at 44691000.0 for Q1 2026.

• On a quarterly basis, Cash from Operations fell 1.44% year-over-year to 44691000.0 in Q1 2026; TTM through Mar 2026 was 111844000.0, a 35.88% increase from a year earlier, with the FY2025 full-year figure at 111209000.0, up 46.03% from the prior year.
• Cash from Operations fell to 44691000.0 in Q1 2026 per PACB's latest filing, from 19069000.0 in the prior quarter.
• Across five years, Cash from Operations topped out at 18707000.0 in Q3 2025 and bottomed at 94691000.0 in Q1 2023.
• The 5-year median for Cash from Operations is 54263000.0 (2024), against an average of 52020117.65.
• Across the five-year window, Cash from Operations plunged 285.46% in 2022 and soared 58.85% in 2025, its largest moves.
• Year by year, Cash from Operations stood at 60566000.0 in 2022, then grew by 4.96% to 57560000.0 in 2023, then jumped by 46.75% to 30650000.0 in 2024, then jumped by 37.78% to 19069000.0 in 2025, then plunged by 134.36% to 44691000.0 in 2026.
• Per Business Quant, the three latest PACB Cash from Operations figures stand at 44691000.0 (Q1 2026), 19069000.0 (Q4 2025), and 18707000.0 (Q3 2025).